We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASR icon
151
Grupo Aeroportuario del Sureste
ASR
$8.39B
$37.5K ﹤0.01%
135
– –
EQIX icon
152
Equinix
EQIX
$101B
$31.4K ﹤0.01%
40
– –
EVTC icon
153
Evertec
EVTC
$1.87B
$27.2K ﹤0.01%
739
– –
KZR
154
DELISTED
Kezar Life Sciences
KZR
$24.5K ﹤0.01%
1,000
– –
UMC icon
155
United Microelectronic
UMC
$53.3B
$21.3K ﹤0.01%
2,698
– –
INFY icon
156
Infosys
INFY
$46.5B
$18.2K ﹤0.01%
1,130
– –
BMY icon
157
Bristol-Myers Squibb
BMY
$124B
– –
-1,496
Closed -$104K
BNTX icon
158
BioNTech
BNTX
$23.1B
– –
-196,480
Closed -$24.5M
CAH icon
159
Cardinal Health
CAH
$53.5B
– –
-10,600
Closed -$800K
HALO icon
160
Halozyme
HALO
$9.23B
– –
-742,400
Closed -$28.4M
HRMY icon
161
Harmony Biosciences
HRMY
$1.96B
– –
-598,046
Closed -$19.5M
HSIC icon
162
Henry Schein
HSIC
$10B
– –
-1,043
Closed -$85K
IPGP icon
163
IPG Photonics
IPGP
$4.43B
– –
-1,050
Closed -$129K
PFE icon
164
Pfizer
PFE
$143B
– –
-740,695
Closed -$30.2M
XNCR icon
165
Xencor
XNCR
$1.3B
– –
-25,400
Closed -$708K
ZLAB icon
166
Zai Lab
ZLAB
$2.28B
– –
-159,400
Closed -$5.3M
ISEE
167
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-52,900
Closed -$1.29M
OPT
168
DELISTED
Opthea Limited American Depositary Shares
OPT
– –
-47,000
Closed -$186K
3 4 5 6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.